This is a renewal of Program Project P01AG04953. It represents a closely integrated series of studies on the cognitive and neurophysiological concomitants of the early stages of Alzheimer's disease (AD). The Central hypothesis of the research program is that AD follows a lengthy tracjectory before full blown symptoms are evident and that, in late-onset cases, disease is the result of multiple converging factors. By merging the measurement of several aspects of cognition and brain function, patients in the very earliest stages of AD can be identified with considerable accuracy. Three interrelated areas are included: Neuropsychological assessment (Project 1), single photon emission computed tomography (SPECT) (Project 2) and functional magnetic resonance imaging (fMR) (Project 3). Four cores will provide essential support to the projects: The Administrative and Clinical core (Core A) will be responsible for subject recruitment, evaluation, and follow-up, the Data Management and Statistical Core (Core B) with maintain a Core Data Base and complete complex statistical analyses; the Genetics Core (Core C) will provide genotyping and the Image Analysis Core (Core D) will perform MRI image analysis relevant to the other projects.

Agency
National Institute of Health (NIH)
Institute
National Institute on Aging (NIA)
Type
Research Program Projects (P01)
Project #
5P01AG004953-16
Application #
6043012
Study Section
Special Emphasis Panel (ZAG1-PCR-5 (M4))
Project Start
1984-08-01
Project End
2002-07-31
Budget Start
1999-08-01
Budget End
2000-07-31
Support Year
16
Fiscal Year
1999
Total Cost
Indirect Cost
Name
Massachusetts General Hospital
Department
Type
DUNS #
City
Boston
State
MA
Country
United States
Zip Code
02199
Tosto, Giuseppe; Monsell, Sarah E; Hawes, Stephen E et al. (2016) Progression of Extrapyramidal Signs in Alzheimer's Disease: Clinical and Neuropathological Correlates. J Alzheimers Dis 49:1085-93
Herold, C; Hooli, B V; Mullin, K et al. (2016) Family-based association analyses of imputed genotypes reveal genome-wide significant association of Alzheimer's disease with OSBPL6, PTPRG, and PDCL3. Mol Psychiatry 21:1608-1612
D'Avanzo, Carla; Aronson, Jenna; Kim, Young Hye et al. (2015) Alzheimer's in 3D culture: challenges and perspectives. Bioessays 37:1139-48
Weissmiller, April M; Natera-Naranjo, Orlangie; Reyna, Sol M et al. (2015) A ?-secretase inhibitor, but not a ?-secretase modulator, induced defects in BDNF axonal trafficking and signaling: evidence for a role for APP. PLoS One 10:e0118379
Liu, Qing; Waltz, Shannon; Woodruff, Grace et al. (2014) Effect of potent ?-secretase modulator in human neurons derived from multiple presenilin 1-induced pluripotent stem cell mutant carriers. JAMA Neurol 71:1481-9
Liang, Steven H; Yokell, Daniel L; Jackson, Raul N et al. (2014) Microfluidic continuous-flow radiosynthesis of [(18)F]FPEB suitable for human PET imaging. Medchemcomm 5:432-435
Choi, Se Hoon; Kim, Young Hye; Hebisch, Matthias et al. (2014) A three-dimensional human neural cell culture model of Alzheimer's disease. Nature 515:274-8
Macklin, Eric A; Blacker, Deborah; Hyman, Bradley T et al. (2013) Improved design of prodromal Alzheimer's disease trials through cohort enrichment and surrogate endpoints. J Alzheimers Dis 36:475-86
Johnson, Keith A; Sperling, Reisa A; Gidicsin, Christopher M et al. (2013) Florbetapir (F18-AV-45) PET to assess amyloid burden in Alzheimer's disease dementia, mild cognitive impairment, and normal aging. Alzheimers Dement 9:S72-83
Fung, Wai Lun Alan; Naylor, Melissa G; Bennett, David A et al. (2013) Principal components methods for narrow-sense heritability in the analysis of multidimensional longitudinal cognitive phenotypes. Am J Med Genet B Neuropsychiatr Genet 162B:770-8

Showing the most recent 10 out of 104 publications